Mounjaro and urinary side effects: what the clinical evidence shows

What the trial data actually recorded about urinary symptoms

The SURMOUNT-1 programme, whose findings were published in the New England Journal of Medicine, tracked adverse events across more than 2,500 adults over 72 weeks. Urinary tract infections appeared on the adverse event list for tirzepatide at all doses tested, classified as uncommon — meaning they occurred in fewer than 1 in 10 but more than 1 in 100 participants. Kidney-related adverse events were also monitored; again, rates were low but higher than in the placebo group.

The Mounjaro SmPC, published on the Electronic Medicines Compendium, lists urinary tract infection under the recognised adverse reactions section. That listing reflects pooled data from the full SURMOUNT and SURPASS clinical programme, covering thousands of adults. It does not mean UTIs are likely for any individual; it means the signal was consistent enough to include in prescriber and patient documentation.

Why might this happen? GLP-1 and GIP receptor agonism affects glucose regulation, and even in people without diabetes, fluctuations in glucose excretion via the kidneys are possible. Higher urinary glucose can create a more hospitable environment for bacterial growth. Separately, if you want a thorough grounding in how Mounjaro side effects present across different body systems, that broader context helps explain why the GI effects common to tirzepatide treatment (nausea, vomiting, diarrhoea) can lead to mild dehydration, which concentrates urine and reduces the flushing action that normally clears bacteria from the lower urinary tract. Neither mechanism is unique to Mounjaro, but both are worth understanding.

How dehydration links GI and urinary symptoms during tirzepatide treatment

A question our prescribers hear most weeks: "I'm having stomach problems and now I've got a UTI, are they connected?" The honest answer is: possibly, yes. Persistent nausea or loose stools reduce your fluid intake and increase fluid losses. The kidneys compensate by concentrating urine; less frequent voiding gives bacteria longer to establish. The result can be a UTI that feels unrelated to a weight-loss injection but shares a common upstream cause.

The NHS tirzepatide patient information page notes that gastrointestinal symptoms are among the most common early effects of treatment, particularly in the first weeks of a new dose. Managing those symptoms well (sipping fluids steadily, eating smaller meals, not skipping meals entirely) reduces the dehydration risk and, by extension, may reduce urinary vulnerability.

This matters most in the titration phase. The early doses of Mounjaro are partly about letting the body adjust, and GI burden tends to ease as that adjustment happens. Our guide to the five most commonly reported Mounjaro side effects explains what that adjustment period typically looks like and when symptoms usually settle. If you are several weeks into a dose and still struggling with nausea or persistent diarrhoea, that is a conversation to have with your prescriber rather than something to push through alone.

When urinary symptoms need prompt medical attention

Most UTIs in otherwise healthy adults resolve quickly with a short antibiotic course and do not require emergency care. But some presentations during Mounjaro treatment do need same-day or urgent assessment. Seek help promptly from your GP, urgent care centre or by calling 111 if you experience any of the following.

Burning or pain on urination combined with fever, rigors (shaking chills), or pain in your side or lower back can indicate a kidney infection (pyelonephritis) rather than a simple bladder infection. Kidney infections need antibiotic treatment promptly and occasionally hospital admission. Blood in the urine (haematuria) alongside other urinary symptoms also warrants a same-day call. And if severe abdominal pain accompanies urinary symptoms, bear in mind that the MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a known (though infrequent) effect of GLP-1 medicines; the location of pancreatic pain can sometimes overlap with flank or back pain. Pancreatitis is a separate condition, but the symptom overlap is worth naming so you don't dismiss significant pain.

If you are unsure whether what you are experiencing is serious, that is reason enough to call rather than wait. It is also worth knowing that some people only notice side effects in certain circumstances on Mounjaro, which can make it harder to judge when something genuinely needs attention; tell any clinician you see that you are taking tirzepatide, it helps them form an accurate picture quickly. The broader side-effect profile of Mounjaro covers other presentations that benefit from the same prompt approach.

What to do in practice, and how nume supports you

If you develop a suspected UTI while on Mounjaro, the practical steps are: see your GP (or use an urgent same-day appointment) for a urine test and, where appropriate, antibiotic treatment. Continue taking Mounjaro unless your prescriber advises otherwise, a UTI alone is not a reason to stop treatment, but your prescriber should know it happened.

Keep up your fluid intake. Aim for pale straw-coloured urine rather than dark yellow; if nausea makes large drinks difficult, small sips of water, diluted squash or clear broth throughout the day all count. Avoid holding urine for long periods, and urinate promptly after sexual activity if UTIs are a pattern for you.

At nume, every repeat supply involves a fresh clinical review. If you report urinary symptoms during that review (or contact our aftercare team at any point in the week) a prescriber considers whether any aspect of your treatment plan needs adjusting. It is one reason the clinical infrastructure behind the service matters: some patients find they experience few or no Mounjaro side effects at all, while others need more active support, and neither outcome should come as a surprise when you have a prescriber checking in regularly. You can also report any suspected reaction linked to tirzepatide directly to the MHRA at yellowcard.mhra.gov.uk.

Thinking about starting treatment and want to understand the full picture? Our prescribers discuss suitability and side effects as part of every consultation. Check your eligibility and start a free consultation.